The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

This comes after the FDA said in October that Eli Lilly weight-loss treatments Mounjaro and Zepbound (which use the active ingredient tirzepatide, rather than semaglutide) were no longer on its list ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Demand GLP-1 Medications as Prescription Drug Market GrowsSchaumburg, Illinois, Feb 21, 2025 - (ACN Newswire) - Giftify, Inc.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

Giftify (GIFT) announced that CardCash.com is offering consumers smart saving solutions for high-cost GLP-1 weight loss prescription ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.